Ruijin Hospital (上海交通大学医学院附属瑞金医院), affiliated with Shanghai Jiao Tong University School of Medicine, has been ranked in China’s top 3 hospitals for over a decade. Founded in 1907, it carries over a century of clinical tradition combined with world-class CAR-T cell therapy, haematology, and endocrinology. Its International Medical Centre (IMC) is one of Shanghai’s most experienced units for international patient coordination. China Care conducts a proxy consultation at Ruijin on your behalf before you travel, then provides bilingual escort throughout your stay.
197 Ruijin 2nd Road, Huangpu District, Shanghai — central location, accessible from both airports
Quick Facts
Payment
RMB only — paid directly to hospital
Consultation
In-person only at IMC
Advance booking
1–2 weeks minimum
Language
English (IMC) + bilingual escort
Type
Public hospital · Grade 3A · SJTU affiliated
Top 3
National hospital ranking
CAR-T
NMPA-approved protocols
IMC
International patient centre
1907
Century of medical history
About the Hospital
A Century of Excellence — Shanghai’s Top-3 General Hospital
Ruijin Hospital (上海交通大学医学院附属瑞金医院) was founded in 1907 by French missionaries as St Marie Hospital in the French Concession of Shanghai. Today, as an affiliate of Shanghai Jiao Tong University School of Medicine, it consistently ranks in China’s top 3 hospitals and serves as a national reference centre for haematology, endocrinology, and cardiovascular medicine.
The hospital’s haematology department is one of China’s most respected, with deep expertise in NMPA-approved CAR-T protocols, bone marrow transplantation for lymphoma, leukaemia, and multiple myeloma, and complex haematological malignancies. Ruijin’s haematology team has been involved in landmark Chinese clinical trials for novel haematological therapies and is a reference centre for difficult or relapsed cases referred from across China.
The International Medical Centre (IMC) at Ruijin is one of Shanghai’s most experienced for international patient coordination. Staff are well-versed in the documentation required for S2 medical visa applications and have supported hundreds of international patients through the process. China Care works directly with the IMC to coordinate case referrals, ensure smooth admissions, and manage documentation for both treatment and visa purposes.
"Ruijin’s depth in haematology and endocrinology reflects over a century of clinical development — combined with an IMC that genuinely understands what international patients need to navigate China’s healthcare system."
Why Patients Choose Ruijin Hospital
Three reasons international patients choose Ruijin Hospital Shanghai
IMC S2 Visa Expertise
Ruijin’s International Medical Centre has processed hundreds of medical visa invitation letters for international patients seeking haematology, oncology, and endocrinology care. The IMC team understands exactly what documentation Chinese embassies require. China Care coordinates directly with the IMC to ensure your visa support documents are complete and consistent, minimising the risk of application delays or rejections.
Haematology & CAR-T Leadership
Ruijin’s haematology department runs NMPA-approved CAR-T cell therapy protocols for B-cell lymphoma, acute lymphoblastic leukaemia, and multiple myeloma. The bone marrow transplant unit is one of Shanghai’s most active, with strong outcomes in allogeneic transplantation for AML, ALL, and lymphoma. Multiple active haematology trials provide access to investigational agents for relapsed and refractory cases.
Endocrinology & Diabetes
Ruijin is one of China’s leading centres for complex endocrinology — type 1 diabetes, type 2 diabetes with complications, thyroid disease (Graves’, Hashimoto’s, thyroid cancer), adrenal disorders, pituitary disease, and metabolic conditions. Its endocrinology department has one of the longest patient outcome databases in China and is involved in major national diabetes research programmes.
Clinical Departments
Specialties Available to International Patients
Ruijin Hospital covers more than 40 clinical departments. Below are those most frequently accessed by international patients through China Care.
Primary Focus
Haematology & CAR-T
NMPA-approved CAR-T protocols for B-cell lymphoma, ALL, and multiple myeloma. High-volume bone marrow transplant unit. Active clinical trials for relapsed/refractory haematological malignancies. National reference centre for complex haematological cases referred from across China.
Nationally ranked endocrinology department. Complex type 1 and type 2 diabetes management, insulin pump therapy, thyroid disease, Graves’ ophthalmopathy, adrenal insufficiency, Cushing’s syndrome, pituitary disorders. One of China’s largest endocrine disease outcome databases.
Complex DiabetesThyroid DiseaseAdrenal Disorders
Also Available
Cardiology
Interventional cardiology, coronary angiography, PCI, electrophysiology, and structural heart disease. One of Shanghai’s leading cardiac centres. Strong in managing complex cases where cardiovascular disease coexists with diabetes or haematological conditions.
Comprehensive solid tumour oncology alongside the dedicated haematology programme. Multidisciplinary tumour boards, molecular profiling, immunotherapy. Particularly strong in gastric cancer, colorectal cancer, and lung cancer — all high-volume in Ruijin’s patient population.
Gastric CancerLung CancerImmunotherapy
Also Available
Gastroenterology
High-volume gastroenterology and endoscopy centre. Inflammatory bowel disease (Crohn’s, ulcerative colitis), complex liver disease, advanced endoscopy (ESD, ERCP, EUS). Particularly noted for managing IBD in a population where the condition is rapidly increasing.
IBD SpecialistAdvanced EndoscopyLiver Disease
Access via China Care
Not sure which department?
Submit your records to China Care. We identify the right specialist team at Ruijin, conduct a proxy consultation on your behalf, and confirm suitability before you commit to travelling.
China Care coordinates the full intake process for international patients, from initial record submission through to on-the-ground support during your stay in Shanghai.
Step 1
Submit Your Records to China Care
Share your medical records, test results, and diagnosis. For haematology cases, include bone marrow biopsy, molecular markers, prior treatment history, and CD19/BCMA expression results for CAR-T eligibility assessment. For endocrinology cases, include HbA1c history, hormone panels, and any relevant imaging. China Care prepares a bilingual case summary for the relevant Ruijin department within 1–2 working days.
records review · 1–2 days
Step 2
China Care Conducts a Proxy Consultation on Your Behalf
China Care attends Ruijin Hospital in person and consults directly with the relevant specialist — on your behalf, before you travel. The doctor reviews your case summary, indicates whether treatment is suitable, and gives an initial direction. China Care reports the outcome back to you with voice call interpretation in real time during the consultation.
This service is charged at a fixed fee, which covers hospital registration, the in-person proxy consultation, and real-time voice interpretation. Already in China? Skip this step — China Care can arrange direct escort and interpretation for your own visit instead.
proxy consultation · fixed fee · results same day
Step 3
Travel to Shanghai for Your In-Person Consultation
Armed with the specialist’s initial direction, you travel to Shanghai for your own in-person consultation at Ruijin. The specialist reviews your case in person, confirms the treatment plan, and issues a formal cost estimate — this step cannot be completed remotely at a public hospital. China Care’s bilingual coordinator accompanies you throughout. For CAR-T and BMT cases, the haematology team will confirm eligibility at this appointment.
in-person consultation · treatment plan & cost estimate issued
Step 4
Admission & Treatment
China Care coordinates your hospital admission through the IMC. For CAR-T therapy, leukapheresis (T-cell collection) occurs first, followed by a manufacturing period of approximately 7–21 days, then lymphodepletion and CAR-T infusion. China Care coordinates accommodation and logistics during the manufacturing wait period. For BMT cases, conditioning begins after admission. For endocrinology cases, outpatient treatment allows flexible scheduling.
All treatment fees are paid directly to the hospital in Chinese yuan (RMB). Ruijin does not accept international credit cards for inpatient treatment. A deposit is required at admission; the balance is settled before discharge. China Care does not collect or handle medical payments.
IMC admission · RMB payment direct to hospital
Step 5
Discharge and Follow-Up
Full discharge documentation is provided including treatment summary, laboratory results, and follow-up monitoring plan. For CAR-T and BMT patients, a detailed post-treatment monitoring schedule is established before discharge. For endocrinology patients, ongoing management guidance including medication protocols is provided in written form for your home physician. China Care ensures all documentation is prepared in a format compatible with your home doctor.
bilingual documentation · monitoring plan · post-discharge support
Proxy consultation (fixed fee)Bilingual case coordinationNMPA-approved CAR-T protocolsHigh-volume BMT unitIn-person escort & interpretationRMB payment direct to hospitalBilingual discharge documentsPost-discharge coordination
Before You Travel
What international patients need to know
Payment
RMB only
All fees paid directly to hospital in Chinese yuan. No international credit cards for inpatient treatment. Deposit required at admission.
Advance booking
1–2 weeks minimum
Walk-in not available for international patients. All appointments booked through China Care before you travel.
Consultation type
In-person only
Public hospital. All specialist consultations take place in person at the IMC. Remote pre-consultation not available.
Language
English + bilingual escort
IMC physicians typically speak functional English. Ward staff: Mandarin. China Care arranges escort for Arabic, Russian, and other languages.
From airport
~20–45 min taxi
Huangpu District is central. ~45 min from Pudong Airport; ~25 min from Hongqiao Airport. Metro Line 9 / Line 13 available.
Hospital type
Public · Grade 3A · Top 3 nationally
Government-funded. China’s highest hospital classification. Treatment costs quoted directly by the hospital — zero treatment markup from China Care.
Common Questions
What patients ask about Ruijin Hospital Shanghai
Who is eligible for CAR-T therapy at Ruijin Hospital?
NMPA-approved CAR-T at Ruijin is available for adults with relapsed or refractory B-cell non-Hodgkin lymphoma, B-cell acute lymphoblastic leukaemia, or multiple myeloma who have received at least two prior lines of therapy. Eligibility requires adequate performance status (typically ECOG 0–2), sufficient organ function, and appropriate CD19 or BCMA expression on tumour cells. China Care submits your case to Ruijin’s haematology team for a pre-travel eligibility assessment. See our complete CAR-T therapy guide for detailed eligibility criteria.
How long does the CAR-T process take from arrival to treatment?
The CAR-T process begins with leukapheresis (T-cell collection) — typically on the day of or shortly after admission. Your T cells are sent to the manufacturer for CAR-T product production, which takes 7–21 days for standard commercial products. Gracell’s FasTCAR platform achieves next-day manufacturing — the cell engineering step itself is completed within 24 hours — for eligible protocols, though the overall treatment timeline from admission to discharge remains approximately 4–6 weeks. During the manufacturing wait, patients typically remain in Shanghai for monitoring. Plan for a total stay of approximately 5–8 weeks from leukapheresis to discharge after post-infusion monitoring.
How does Ruijin’s IMC handle the documentation process for international patients?
Ruijin’s IMC issues official hospital documentation once a consultation has been confirmed, including letters that specify the treating department, estimated treatment duration, and the attending physician’s details. China Care prepares the full supporting documentation package for your specific nationality and guides you through the requirements. The IMC team is experienced with the documentation requirements of multiple nationalities and understands which additional supporting materials specific embassies sometimes request.
Is Ruijin also a good option for non-haematological conditions?
Yes — Ruijin’s endocrinology department is one of the best in China for complex diabetes management, thyroid disease, and metabolic disorders. Its cardiology programme is among Shanghai’s strongest. For patients with complex multi-system conditions (e.g., lymphoma plus significant cardiac comorbidity, or cancer plus severe diabetes), Ruijin’s breadth as a top-3 general hospital is an advantage over a dedicated cancer centre. China Care helps you determine whether Ruijin or a specialist institution is the better fit for your overall clinical picture.
How does payment work at Ruijin Hospital?
All treatment fees are paid directly to Ruijin Hospital in Chinese yuan (RMB). As a public hospital, Ruijin does not accept international credit cards for inpatient treatment or surgery. A deposit is typically required at admission; the remaining balance is settled before discharge. We advise patients to arrange RMB exchange before arrival. Payment is made directly to the hospital. China Care does not collect or process medical payments on your behalf; your coordination fee is paid to China Care separately and in advance.
What is the difference between the IMC ward and the general ward at Ruijin?
The IMC wing at Ruijin offers private or semi-private rooms, international patient coordinators, and dedicated administrative staff. General wards are multi-bed with shared facilities and are designed primarily for Chinese-speaking patients with domestic insurance. International patients admitted through China Care’s referral are accommodated through the IMC pathway, which provides a significantly better experience during inpatient stays. Clinical care quality — physician skill and treatment protocols — is identical across both settings. The IMC primarily improves accommodation, administrative support, and communication assistance.
Get Started
Ready to access treatment at Ruijin Hospital Shanghai?
Submit your records to China Care. We conduct a proxy consultation at Ruijin on your behalf and report back before you commit to travelling.
China Care coordinates your case with Ruijin Hospital’s International Medical Centre. Treatment costs are quoted directly by the hospital. We never add to or mark up the hospital’s quoted treatment cost.
